SERPINB11 Expression Is Associated With Prognosis of High-grade Serous and Clear Cell Carcinoma of the Ovary
- Authors
- Park, Soo Jin; Lim, Whasun; Mun, Jaehee; Paik, Haerin; Park, Sunwoo; Lim, Hyunji; Kim, Junhwan; Lee, Eun Ji; Yim, Ga Won; Lee, Nara; Lee, Cheol; Kim, Jae-Weon; Song, Gwonhwa; Kim, Hee Seung
- Issue Date
- Sep-2021
- Publisher
- INT INST ANTICANCER RESEARCH
- Keywords
- High-grade serous; clear cell; ovarian cancer; SERPINB11; prognosis
- Citation
- IN VIVO, v.35, no.5, pp 2647 - 2653
- Pages
- 7
- Journal Title
- IN VIVO
- Volume
- 35
- Number
- 5
- Start Page
- 2647
- End Page
- 2653
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74158
- DOI
- 10.21873/invivo.12547
- ISSN
- 0258-851X
1791-7549
- Abstract
- Background/Aim: To evaluate the role of serine protease inhibitor B11 (SERPINB11) expression as a prognostic biomarker in high-grade serous carcinoma (HGSC) and clear cell carcinoma of the ovary (CCC). Materials and Methods: We obtained tumor tissues from patients with HGSC (n=145) and CCC (n=59). We evaluated immunohistochemically the expression of SERPINB11 and investigated whether SERPINB11 expression affects platinum-resistance and the prognosis of HGSC and CCC. Results: High expression of SERPINB11 was more common in CCC than in HGSC (57.6% vs. 28.3%; p<0.01), and SEPRINB11 expression did not correlate with platinum-resistance of HGSC and CCC. High expression of SERPINB11 was associated with worse progression-free survival and overall survival with marginal significance in HGSC; no relation between SERPINB11 expression and the prognosis of CCC was found. Conclusion: SERPINB11 expression maybe a prognostic biomarker for HGSC.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74158)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.